Aclarion Partners with Advocate Health for Nociscan Trial
Aclarion Partners with Advocate Health for Nociscan Trial
Aclarion, Inc., a forward-thinking healthcare technology company, has taken a significant step in chronic low back pain research by partnering with Advocate Health. This collaboration involves the integration of Advocate Aurora Research Institute as a pivotal site for the CLARITY trial, aimed at validating the effectiveness of the innovative diagnostic tool, Nociscan.
About Advocate Health’s Involvement
Advocate Health is well-known for its commitment to advancing healthcare through research and technology. The institute engages in various research projects each year, translating cutting-edge findings into improved patient care and treatment strategies. According to Patrick Sugrue, MD, a neurosurgeon at Advocate Health, their participation in this trial promises to bring significant improvements in diagnosing and treating patients suffering from chronic low back pain, a condition that is notoriously challenging to diagnose accurately.
The Potential of Nociscan
Nociscan is designed to revolutionize the way chronic low back pain is approached, leveraging advanced technologies like Magnetic Resonance Spectroscopy (MRS) and augmented intelligence. This innovative platform enables practitioners to differentiate between painful and non-painful discs in the lumbar spine, allowing for tailored treatment plans that could lead to better surgical outcomes. In an era where millions are affected by chronic low back pain globally, Aclarion's approach holds promising potential to redefine surgical protocols.
The CLARITY Trial: What You Need to Know
The CLARITY trial stands for Chronic Low back pain Randomized Independent Trial study and is a carefully structured, randomized multi-center study targeting patients undergoing surgical intervention for discogenic low back pain. The trial will enroll approximately 300 patients across several high-volume sites in the United States, with a focus on assessing the efficacy of the Nociscan platform before surgical procedures begin.
Trial Structure and Methodology
This study employs a randomized approach, ensuring that participating surgeons are either blinded or unblinded to the Nociscan results. By comparing surgical outcomes determined by the Nociscan platform against traditional diagnostic methods, the trial aims to establish a robust data set that highlights Nociscan’s clinical and economic value in spine surgery.
Chronic Low Back Pain: A Global Challenge
The issue of chronic low back pain transcends borders, impacting approximately 266 million people worldwide. Traditional imaging techniques often fail to provide clear insights into pain origins, leading to misdiagnoses and ineffective treatments. Aclarion’s Nociscan serves as a much-needed solution, objective in its quantification of chemical biomarkers tied to disc pain.
The Future of Pain Management
With advancements in diagnostic technologies like Nociscan, physicians will soon be equipped to better pinpoint painful disc locations, which could lead to more effective treatments for patients. This not only enhances the quality of care but could potentially minimize the surgical risks associated with mistaken diagnoses.
Looking Ahead
As Aclarion embarks on this exciting venture with Advocate Health, the focus on improving chronic low back pain management is more pertinent than ever. The collaboration aims to shed light on the clinical capabilities of the Nociscan platform, driving forward the evolution of spine surgery and patient outcomes.
Frequently Asked Questions
What is the purpose of the CLARITY trial?
The CLARITY trial aims to assess the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain.
How will Nociscan change the diagnosis of back pain?
Nociscan provides an innovative method for distinguishing between painful and non-painful discs, enhancing treatment precision.
Who is leading the CLARITY trial?
The trial is spearheaded by Dr. Nicholas Theodore of Johns Hopkins Medicine, ensuring credibility and expertise in its execution.
What advancements does Nociscan utilize?
Nociscan leverages Magnetic Resonance Spectroscopy (MRS) and augmented intelligence to assess chronic low back pain effectively.
How many patients will be enrolled in the trial?
The study will enroll about 300 patients across various high-volume clinical sites in the United States.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.